Valneva Se (VALN)

$8.1299

+0.38

(+4.9%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Valneva Se

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 38.07M → 41.89M (in $), with an average increase of 9.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -34.22M → -32.15M (in $), with an average increase of 6.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 78.1%

Performance

  • $7.76
    $8.22
    $8.13
    downward going graph

    4.55%

    Downside

    Day's Volatility :5.6%

    Upside

    1.09%

    downward going graph
  • $6.58
    $17.05
    $8.13
    downward going graph

    19.07%

    Downside

    52 Weeks Volatility :61.41%

    Upside

    52.32%

    downward going graph

Returns

PeriodValneva SeSector (Health Care)Index (Russel 2000)
3 Months
-13.02%
-0.7%
0.0%
6 Months
-29.48%
6.6%
0.0%
1 Year
-27.0%
3.7%
-1.5%
3 Years
-73.35%
14.0%
-21.8%

Highlights

Market Capitalization
595.0M
Book Value
$0.92
Earnings Per Share (EPS)
-1.55
Wall Street Target Price
17.92
Profit Margin
-65.99%
Operating Margin TTM
-74.67%
Return On Assets TTM
-10.23%
Return On Equity TTM
-58.29%
Revenue TTM
153.7M
Revenue Per Share TTM
2.22
Quarterly Revenue Growth YOY
-79.10000000000001%
Gross Profit TTM
-68.1M
EBITDA
-76.7M
Diluted Eps TTM
-1.55
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.15
EPS Estimate Next Year
-0.76
EPS Estimate Current Quarter
0.12
EPS Estimate Next Quarter
0.47

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Valneva Se(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 120.42%

Current $8.13
Target $17.92

Company Financials

FY18Y/Y Change
Revenue
129.3M
↑ 7.35%
Net Income
3.7M
↓ 128.43%
Net Profit Margin
2.89%
↑ 13.8%
FY19Y/Y Change
Revenue
141.4M
↑ 11.64%
Net Income
-2.0M
↓ 153.43%
Net Profit Margin
-1.38%
↓ 4.27%
FY20Y/Y Change
Revenue
135.7M
↓ 12.58%
Net Income
-79.2M
↑ 3592.26%
Net Profit Margin
-58.37%
↓ 56.99%
FY21Y/Y Change
Revenue
394.2M
↑ 215.52%
Net Income
-83.2M
↑ 14.03%
Net Profit Margin
-21.09%
↑ 37.28%
FY22Y/Y Change
Revenue
387.0M
↑ 3.8%
Net Income
-153.5M
↑ 95.14%
Net Profit Margin
-39.66%
↓ 18.57%
FY23Y/Y Change
Revenue
153.7M
↓ 57.46%
Net Income
-101.4M
↓ 29.21%
Net Profit Margin
-65.99%
↓ 26.33%
Q3 FY22Q/Q Change
Revenue
154.0M
↑ 617.13%
Net Income
71.2M
↓ 378.09%
Net Profit Margin
46.22%
↑ 165.41%
Q4 FY22Q/Q Change
Revenue
35.9M
↓ 78.61%
Net Income
-19.4M
↓ 125.03%
Net Profit Margin
-54.1%
↓ 100.32%
Q1 FY23Q/Q Change
Revenue
36.5M
↑ 0.0%
Net Income
-19.8M
↑ 0.0%
Net Profit Margin
-54.1%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
43.9M
↑ 20.08%
Net Income
-18.5M
↓ 6.66%
Net Profit Margin
-42.05%
↑ 12.05%
Q3 FY23Q/Q Change
Revenue
38.1M
↓ 5.38%
Net Income
-34.2M
↑ 102.29%
Net Profit Margin
-89.9%
↓ 47.85%
Q4 FY23Q/Q Change
Revenue
41.9M
↑ 10.05%
Net Income
-32.2M
↓ 6.04%
Net Profit Margin
-76.75%
↑ 13.15%
FY18Y/Y Change
Total Assets
263.0M
↑ 21.42%
Total Liabilities
99.2M
↓ 10.3%
FY19Y/Y Change
Total Assets
296.5M
↑ 15.14%
Total Liabilities
145.1M
↑ 49.41%
FY20Y/Y Change
Total Assets
552.5M
↑ 69.67%
Total Liabilities
457.2M
↑ 186.9%
FY21Y/Y Change
Total Assets
925.7M
↑ 81.97%
Total Liabilities
732.5M
↑ 73.98%
FY22Y/Y Change
Total Assets
665.6M
↓ 23.98%
Total Liabilities
430.2M
↓ 37.92%
FY23Y/Y Change
Total Assets
469.4M
↓ 24.46%
Total Liabilities
341.1M
↓ 15.04%
Q3 FY22Q/Q Change
Total Assets
686.2M
↓ 3.73%
Total Liabilities
524.0M
↓ 15.63%
Q4 FY22Q/Q Change
Total Assets
632.0M
↓ 15.48%
Total Liabilities
412.7M
↓ 27.74%
Q1 FY23Q/Q Change
Total Assets
643.4M
↑ 0.0%
Total Liabilities
420.1M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
592.0M
↓ 8.04%
Total Liabilities
383.9M
↓ 8.66%
Q3 FY23Q/Q Change
Total Assets
520.5M
↓ 4.06%
Total Liabilities
363.0M
↑ 3.17%
Q4 FY23Q/Q Change
Total Assets
469.4M
↓ 9.83%
Total Liabilities
341.1M
↓ 6.03%
FY18Y/Y Change
Operating Cash Flow
18.7M
↑ 27.1%
Investing Cash Flow
-3.3M
↓ 28.15%
Financing Cash Flow
35.4M
↓ 396.46%
FY19Y/Y Change
Operating Cash Flow
6.2M
↓ 66.09%
Investing Cash Flow
-12.0M
↑ 266.3%
Financing Cash Flow
-8.6M
↓ 124.87%
FY20Y/Y Change
Operating Cash Flow
169.4M
↑ 2391.19%
Investing Cash Flow
-23.8M
↑ 81.0%
Financing Cash Flow
26.7M
↓ 382.48%
FY21Y/Y Change
Operating Cash Flow
87.1M
↓ 44.17%
Investing Cash Flow
-105.5M
↑ 381.47%
Financing Cash Flow
175.0M
↑ 610.69%
Q3 FY22Q/Q Change
Operating Cash Flow
-87.8M
↑ 232.52%
Investing Cash Flow
-6.4M
↓ 0.89%
Financing Cash Flow
16.3M
↑ 1592.97%
Q4 FY22Q/Q Change
Operating Cash Flow
-26.1M
↓ 72.75%
Investing Cash Flow
-3.3M
↓ 52.69%
Financing Cash Flow
-4.1M
↓ 122.95%
Q1 FY23Q/Q Change
Operating Cash Flow
-26.5M
↑ 0.0%
Investing Cash Flow
-3.3M
↑ 0.0%
Financing Cash Flow
-4.2M
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-44.9M
↑ 68.98%
Investing Cash Flow
-3.3M
↑ 0.0%
Financing Cash Flow
-6.2M
↑ 48.32%
Q3 FY23Q/Q Change
Operating Cash Flow
-71.4M
↑ 73.7%
Investing Cash Flow
2.4M
↓ 176.94%
Financing Cash Flow
35.6M
↓ 729.2%

Technicals Summary

Sell

Neutral

Buy

Valneva Se is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Valneva Se
Valneva Se
0.34%
-29.48%
-27.0%
-73.35%
-73.35%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Valneva Se
Valneva Se
72.37
NA
NA
-0.15
-0.58
-0.1
NA
0.92
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Valneva Se
Valneva Se
Buy
$595.0M
-73.35%
72.37
-65.99%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • General American Investors Company Inc

    0.50%

  • AlphaCentric Advisors, LLC

    0.05%

  • LAURION CAPITAL MANAGEMENT LP

    0.04%

  • Morgan Stanley - Brokerage Accounts

    0.01%

Company Information

Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden and Vienna, Austria, with other offices in France, Canada and the United States.

Organization
Valneva Se
Employees
676
CEO
Mr. Thomas Lingelbach
Industry
Healthcare

Discover More

FAQs